Palmer AC - Search Results

1

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.

Palmer AC, Izar B, Hwangbo H, Sorger PK. Palmer AC, et al. Clin Cancer Res. 2022 Jan 15;28(2):368-377. doi: 10.1158/1078-0432.CCR-21-2275. Clin Cancer Res. 2022. PMID: 35045958 Free PMC article.

2

Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Palmer AC, Sorger PK. Palmer AC, et al. Cell. 2017 Dec 14;171(7):1678-1691.e13. doi: 10.1016/j.cell.2017.11.009. Cell. 2017. PMID: 29245013 Free PMC article.

3

Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.

Wang H, Sheehan RP, Palmer AC, Everley RA, Boswell SA, Ron-Harel N, Ringel AE, Holton KM, Jacobson CA, Erickson AR, Maliszewski L, Haigis MC, Sorger PK. Wang H, et al. Among authors: palmer ac. Cell Syst. 2019 May 22;8(5):412-426.e7. doi: 10.1016/j.cels.2019.03.009. Epub 2019 May 8. Cell Syst. 2019. PMID: 31078528 Free PMC article.

4

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

Palmer AC, Chidley C, Sorger PK. Palmer AC, et al. Elife. 2019 Nov 19;8:e50036. doi: 10.7554/eLife.50036. Elife. 2019. PMID: 31742555 Free PMC article.

5

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.

Chopra SS, Jenney A, Palmer A, Niepel M, Chung M, Mills C, Sivakumaren SC, Liu Q, Chen JY, Yapp C, Asara JM, Gray NS, Sorger PK. Chopra SS, et al. Cell Syst. 2020 Jan 22;10(1):66-81.e11. doi: 10.1016/j.cels.2019.11.001. Epub 2019 Dec 4. Cell Syst. 2020. PMID: 31812693 Free PMC article.

6

A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.

Palmer AC, Plana D, Gao H, Korn JM, Yang G, Green J, Zhang X, Velazquez R, McLaughlin ME, Ruddy DA, Kowal C, Muszynski J, Bullock C, Rivera S, Rakiec DP, Elliott G, Fordjour P, Meyer R, Loo A, Kurth E, Engelman JA, Bitter H, Sellers WR, Williams JA, Sorger PK. Palmer AC, et al. Cancer Res. 2020 Oct 1;80(19):4278-4287. doi: 10.1158/0008-5472.CAN-19-3850. Epub 2020 Aug 3. Cancer Res. 2020. PMID: 32747364 Free PMC article.

7

Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials.

Palmer AC, Plana D, Sorger PK. Palmer AC, et al. Cell Syst. 2020 Nov 18;11(5):449-460.e2. doi: 10.1016/j.cels.2020.09.003. Cell Syst. 2020. PMID: 33220857 Free PMC article.

8

Independent Drug Action in Combination Therapy: Implications for Precision Oncology.

Plana D, Palmer AC, Sorger PK. Plana D, et al. Among authors: palmer ac. Cancer Discov. 2022 Mar 1;12(3):606-624. doi: 10.1158/2159-8290.CD-21-0212. Cancer Discov. 2022. PMID: 34983746 Free PMC article. Review.

9

Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects.

Plana D, Fell G, Alexander BM, Palmer AC, Sorger PK. Plana D, et al. Among authors: palmer ac. Nat Commun. 2022 Feb 15;13(1):873. doi: 10.1038/s41467-022-28410-9. Nat Commun. 2022. PMID: 35169116 Free PMC article.

10

Drug independence and the curability of cancer by combination chemotherapy.

Pomeroy AE, Schmidt EV, Sorger PK, Palmer AC. Pomeroy AE, et al. Among authors: palmer ac. Trends Cancer. 2022 Nov;8(11):915-929. doi: 10.1016/j.trecan.2022.06.009. Epub 2022 Jul 14. Trends Cancer. 2022. PMID: 35842290 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters